New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere

Ilan Bruchim, Ilaria Capasso, Ariel Polonsky, Shilhav Meisel, Vanda Salutari, Haim Werner, Domenica Lorusso, Giovanni Scambia, Francesco Fanfani

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

IntroductionEndometrial cancer (EC) is the only gynecologic malignancy showing increasing trends in incidence and mortality. While standard treatment has been effective primarily for early-stage EC, precision medicine with tailored therapy has revolutionized the management of this disease. Genome sequencing analyses have identified four sub-types of EC. Treatments for primary and metastatic disease can now be tailored more accurately to achieve better oncologic results.Areas coveredThis review provides an overview of the most relevant and updated evidence in the literature regarding EC molecular analysis and its role in risk classification, prognostication, and guidance for tailored and target therapies in early and advanced/metastatic stages. In addition, it provides updated information on optimal surgical management based on molecular classification and highlights key advances and future strategies.Expert opinionEC molecular analysis yields the potential of tailoring adjuvant treatment by escalating or deescalating therapy, as shown for POLE-mutated and p53-mutated tumors. Moreover, the expression of specific molecular signatures offers the possibility to employ novel target therapies, such as immune-checkpoint inhibitors that have demonstrated a significant benefit on prognosis. New treatment guidelines are still being established, and ongoing studies are exploring the potential prognostic role of further sub-stratifications of the four molecular classes and treatment options.Endometrial cancer (EC) is the only female cancer that is increasing among women. While the usual treatments work best when the disease is caught early, new advances in genetic studies have greatly improved the management of the disease. Four sub-types of EC have been identified. They are called: POLE-mutated, MMR-deficient, p53-abnormal, and no specific molecular profile. Treatments for EC can now be tailored more accurately to achieve better results. This review gives an overview of the most new and important evidence in the scientific literature about the molecular analysis of EC and how it can be used to help tailor the best treatments and surgeries for women with EC.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaExpert Opinion on Therapeutic Targets
Volume28
DOI
Stato di pubblicazionePubblicato - 2024

Keywords

  • DNA polymerase epsilon ultra-mutated
  • Endometrial cancer
  • microsatellite unstable hypermutated, p-53-abnormal endometrial cancer
  • mismatch repair deficient endometrial cancer
  • molecular classification

Fingerprint

Entra nei temi di ricerca di 'New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere'. Insieme formano una fingerprint unica.

Cita questo